Preclinical Antitumor Efficacy of Analogs of XK469: Sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate

Overview

Journal Invest New Drugs

Publisher Springer

Specialty Oncology

Date 1998 Dec 16

PMID 9848576

Citations 16

Authors

T H Corbett

P Lorusso

L Demchick

C Simpson

S Pugh

K White

J Kushner

L Polin

J Meyer

J Czarnecki

L Heilbrun

J P HORWITZ

J L Gross

C H Behrens

B A Harrison

R J McRipley

G Trainor

Affiliations

Soon will be listed here.

Abstract

A series of quinoxaline analogs of the herbicide Assure was found to have selective cytotoxicity for solid tumors of mice in a disk-diffusion-soft-agar-colony-formation-assay compared to L1210 leukemia. Four agents without selective cytotoxicity and 14 agents with selective cytotoxicity were evaluated in vivo for activity against a solid tumor. The four agents without selective cytotoxicity in the disk-assay were inactive in vivo (T/C > 42%). Thirteen of the fourteen agents with selectivity in the disk-assay were active in vivo (T/C < 42%). Five of the agents had curative activity. These five agents had a halogen (F, Cl, Br) in the 7-position (whereas Assure had a CI in the 6 position). All agents with curative activity were either a carboxylic acid, or a derivative thereof, whereas Assure is the ethyl ester of the carboxylic acid. All other structural features were identical between Assure and the curative agents. Assure had no selective cytotoxicity for solid tumors in the disk-assay, and was devoid of antitumor activity. The analog XK469 is in clinical development.

Citing Articles

Novel quinoxaline-3-propanamides as VGFR-2 inhibitors and apoptosis inducers.

Ismail M, Shawer T, Ibrahim R, Abusaif M, Kamal M, Allam R RSC Adv. 2023; 13(45):31908-31924.

PMID: 37915441 PMC: 10616755. DOI: 10.1039/d3ra05066a.

New quinoxaline-based VEGFR-2 inhibitors: design, synthesis, and antiproliferative evaluation with docking, ADMET, toxicity, and DFT studies.

Alanazi M, Elkady H, Alsaif N, Obaidullah A, Alkahtani H, Alanazi M RSC Adv. 2022; 11(48):30315-30328.

PMID: 35493991 PMC: 9044819. DOI: 10.1039/d1ra05925d.

Targeting Nonsquamous Nonsmall Cell Lung Cancer via the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]Pyrimidine Thienoyl Antifolates.

Wilson M, Hou Z, Yang S, Polin L, Kushner J, White K Mol Pharmacol. 2016; 89(4):425-34.

PMID: 26837243 PMC: 4809305. DOI: 10.1124/mol.115.102798.

Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.

Boerner J, Nechiporchik N, Mueller K, Polin L, Heilbrun L, Boerner S PLoS One. 2015; 10(3):e0119614.

PMID: 25774912 PMC: 4361640. DOI: 10.1371/journal.pone.0119614.

Synthesis of new quinoxalines containing an oxirane ring by the TDAE strategy and in vitro evaluation in neuroblastoma cell lines.

Montana M, Correard F, Khoumeri O, Esteve M, Terme T, Vanelle P Molecules. 2014; 19(9):14987-98.

PMID: 25237753 PMC: 6271844. DOI: 10.3390/molecules190914987.

References

Corbett T, Roberts B, Leopold W, Peckham J, WILKOFF L, Griswold Jr D . Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 1984; 44(2):717-26. View

Corbett T, Valeriote F, Demchik L, Polin L, Panchapor C, Pugh S . Preclinical anticancer activity of cryptophycin-8. J Exp Ther Oncol. 1996; 1(2):95-108. View

Zegar I, Graslund A, Bergman J, Eriksson M, Norden B . Interaction of ellipticine and an indolo[2,3b]-quinoxaline derivative with DNA and synthetic polynucleotides. Chem Biol Interact. 1989; 72(3):277-93. DOI: 10.1016/0009-2797(89)90004-5. View

Conley B, OHara S, Wu S, Melink T, Parnes H, Pardoe E . Phase I trial of chloroguinoxaline sulfonamide, with correlation of its pharmacokinetics and pharmacodynamics. Cancer Chemother Pharmacol. 1995; 37(1-2):139-49. DOI: 10.1007/BF00685641. View

Corbett T, Valeriote F, Baker L . Is the P388 murine tumor no longer adequate as a drug discovery model?. Invest New Drugs. 1987; 5(1):3-20. DOI: 10.1007/BF00217664. View

Corbett T, Griswold Jr D, Roberts B, Peckham J, SCHABEL Jr F . Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 1975; 35(9):2434-9. View

Rigas J, Francis P, Miller V, Tong W, Roistacher N, Kris M . Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule. Cancer Chemother Pharmacol. 1995; 35(6):483-8. DOI: 10.1007/BF00686832. View

Branda R, McCormack J, Perlmutter C . Cellular pharmacology of chloroquinoxaline sulfonamide and a related compound in murine B16 melanoma cells. Biochem Pharmacol. 1988; 37(23):4557-64. DOI: 10.1016/0006-2952(88)90672-7. View

Miller V, Rigas J, Tong W, Reid J, Pisters K, Grant S . Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer. Cancer Chemother Pharmacol. 1997; 40(5):415-8. DOI: 10.1007/s002800050679. View

10.

Corbett T, Griswold Jr D, Roberts B, Peckham J, SCHABEL Jr F . Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer. 1977; 40(5 Suppl):2660-80. DOI: 10.1002/1097-0142(197711)40:5+<2660::aid-cncr2820400940>3.0.co;2-m. View

11.

Corbett T, Roberts B, Trader M, Laster Jr W, Griswold Jr D, SCHABEL Jr F . Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Cancer Treat Rep. 1982; 66(5):1187-200. View

12.

Branda R, Moore A, McCormack J . Immunosuppressive properties of chloroquinoxaline sulfonamide. Biochem Pharmacol. 1989; 38(20):3521-6. DOI: 10.1016/0006-2952(89)90123-8. View

13.

Corbett T, Leopold W, Dykes D, Roberts B, Griswold Jr D, SCHABEL Jr F . Toxicity and anticancer activity of a new triazine antifolate (NSC 127755). Cancer Res. 1982; 42(5):1707-15. View